Literature DB >> 3929464

In vivo demonstration of cytoplasmic fibronectin in human breast carcinomas.

L Christensen, M Nielsen, B Hølund, I Clemmensen.   

Abstract

The distribution pattern of fibronectin in 24 invasive human breast carcinomas has been studied using the indirect immunoperoxidase technique. A positive cytoplasmic staining reaction was observed in 16 tumours. Well-differentiated carcinomas showed weak or no staining, whereas all moderately or poorly differentiated carcinomas and one signet ring cell carcinoma contained fibronectin positive tumour cells with moderate or strong staining. The staining intensity was positively correlated to degree of anaplasia with the exception of two moderately differentiated duct carcinomas and the two medullary carcinomas, which were only slightly positive. Non-attached independently growing tumour cells stained more intensely than tumour cells in clusters. Pericellular fibronectin was found in only one carcinoma of medullary type. In normal ducts and glands it was seen at the stromal-epithelial junction corresponding to the basement membrane, around myoepithelial cells and along the luminal border. The results support the findings of several in vitro investigations that breast tumour cells synthesize fibronectin. It also suggests that cytoplasmic fibronectin expression might be an indicator of tissue differentiation in non-solidly growing invasive duct carcinomas of the human mammary gland.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3929464     DOI: 10.1007/bf00710658

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  35 in total

Review 1.  Fibronectins--adhesive glycoproteins of cell surface and blood.

Authors:  K M Yamada; K Olden
Journal:  Nature       Date:  1978-09-21       Impact factor: 49.962

2.  Immunohistochemical detection of fibronectin using different fixatives in paraffin embedded sections.

Authors:  M Szendröi; J Labat-Robert; G Godeau; A M Robert
Journal:  Pathol Biol (Paris)       Date:  1983-09

3.  Interactions of normal, dysplastic, and malignant mammary epithelial cells with fibronectin in vivo and in vitro.

Authors:  B B Asch; B R Kamat; N A Burstein
Journal:  Cancer Res       Date:  1981-06       Impact factor: 12.701

4.  Immunization, isolation of immunoglobulins, estimation of antibody titre.

Authors:  N Harboe; A Ingild
Journal:  Scand J Immunol Suppl       Date:  1973

5.  Modification of fibronectin distribution pattern in solid human tumours.

Authors:  J Labat-Robert; P Birembaut; L Robert; J J Adnet
Journal:  Diagn Histopathol       Date:  1981 Oct-Dec

6.  Different molecular forms of fibronectin in rheumatoid synovial fluid.

Authors:  I Clemmensen; R B Andersen
Journal:  Arthritis Rheum       Date:  1982-01

7.  Heterogeneous distribution of actin, myosin, fibronectin and basement membrane antigens in primary and metastatic human breast cancer.

Authors:  P G Natali; P Giacomini; G Bigotti; M R Nicotra; M Bellocci; C De Martino
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

8.  Possible role of fibronectin in malignancy.

Authors:  L B Chen; I Summerhayes; P Hsieh; P H Gallimore
Journal:  J Supramol Struct       Date:  1979

9.  Distribution of fibronectin on clonal cell lines of a rat mammary adenocarcinoma growing in vitro and in vivo at primary and metastatic sites.

Authors:  A Neri; E Ruoslahti; G L Nicolson
Journal:  Cancer Res       Date:  1981-12       Impact factor: 12.701

10.  Distribution of fibroblast surface antigen in the developing chick embryo.

Authors:  E Linder; A Vaheri; E Ruoslahti; J Wartiovaara
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

View more
  2 in total

1.  Differentiation between metaplastic carcinomas and sarcomas of the human female breast by fibronectin.

Authors:  L Christensen; M Nielsen; B Hølund; I Clemmensen
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

2.  Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma.

Authors:  R A Walker; S J Dearing; B Gallacher
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.